Company profile: SeQure Dx
1.1 - Company Overview
Company description
- Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
Products and services
- Gene Editing Off-Target Risk Assessment: CRISPR-focused service that assesses and identifies on-target specificity and off-target risks throughout the gene editing therapeutic development lifecycle, delivering safety data for therapy development
- NoteSeQ: Assay-based diagnostic platform utilizing ONE-seq to profile off-target gene editing sites across a range of gene editors, generating safety data for therapeutic decision-making
- ScopeSeQ: NGS-driven confirmation platform validating candidate off-target edits in individual genomes or tissues using next-generation sequencing, supporting verification of edit specificity during CRISPR therapy development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SeQure Dx
Crescendo Bioscience
HQ: United States
Website
- Description: Provider of quantitative, objective diagnostic tools for rheumatologists, delivering clinical insights to manage patients with autoimmune and inflammatory diseases. Provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Bioscience company profile →
Phthisis Diagnostics
HQ: United States
Website
- Description: Provider of molecular diagnostics products for various infectious diseases, leveraging molecular technology to deliver superior quality, ease of use, and cost savings for laboratories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phthisis Diagnostics company profile →
Rewrite Therapeutics
HQ: United States
Website
- Description: Provider of novel DNA writing technologies from a private biotechnology company focused on advancing the field.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rewrite Therapeutics company profile →
Ingenuity
HQ: United States
Website
- Description: Provider of a software platform and information services that enable enterprise customers to give life science researchers access to information via internal portals, search engines, other software, and workflow sources, allowing them to search, explore, visualize, interpret, and analyze complex biological systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ingenuity company profile →
Genomatix
HQ: Germany
Website
- Description: Provider of computational biology software, databases, and services for understanding gene regulation at the molecular level, including sequence analysis, functional promoter analysis, proprietary genome annotation, and promoter sequence databases, plus testing and interpreting genomic data, representing a central part of systems biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomatix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SeQure Dx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SeQure Dx
2.2 - Growth funds investing in similar companies to SeQure Dx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SeQure Dx
4.2 - Public trading comparable groups for SeQure Dx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →